<html xmlns:v="urn:schemas-microsoft-com:vml"xmlns:o="urn:schemas-microsoft-com:office:office"xmlns:w="urn:schemas-microsoft-com:office:word"xmlns="http://www.w3.org/TR/REC-html40"><head><meta name=Title content="OMLAB Report #022005"><meta name=Keywords content=""><meta http-equiv=Content-Type content="text/html; charset=macintosh"><meta name=ProgId content=Word.Document><meta name=Generator content="Microsoft Word 11"><meta name=Originator content="Microsoft Word 11"><link rel=File-List href="NystThpys_files/filelist.xml"><link rel=Edit-Time-Data href="NystThpys_files/editdata.mso"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}o\:* {behavior:url(#default#VML);}w\:* {behavior:url(#default#VML);}.shape {behavior:url(#default#VML);}</style><![endif]--><title>OMLAB Report #022005</title><!--[if gte mso 9]><xml> <o:DocumentProperties>  <o:Subject>Nystagmus Therapies</o:Subject>  <o:Author>L. F. Dell'Osso, Ph.D.</o:Author>  <o:Template>Papers</o:Template>  <o:LastAuthor>OMLAB VAMC</o:LastAuthor>  <o:Revision>2</o:Revision>  <o:LastPrinted>2011-05-04T17:15:00Z</o:LastPrinted>  <o:Created>2011-05-04T17:15:00Z</o:Created>  <o:LastSaved>2011-05-04T17:15:00Z</o:LastSaved>  <o:Pages>2</o:Pages>  <o:Words>1949</o:Words>  <o:Characters>11112</o:Characters>  <o:Company>OMLAB</o:Company>  <o:Lines>92</o:Lines>  <o:Paragraphs>22</o:Paragraphs>  <o:CharactersWithSpaces>13646</o:CharactersWithSpaces>  <o:Version>11.1280</o:Version> </o:DocumentProperties> <o:OfficeDocumentSettings>  <o:AllowPNG/>  <o:PixelsPerInch>300</o:PixelsPerInch> </o:OfficeDocumentSettings></xml><![endif]--><!--[if gte mso 9]><xml> <w:WordDocument>  <w:Zoom>150</w:Zoom>  <w:ActiveWritingStyle Lang="EN-US" VendorID="8" DLLVersion="513" NLCheck="0">1</w:ActiveWritingStyle>  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>  <w:UseMarginsForDrawingGridOrigin/>  <w:DocumentVariables>   <w:EN_Lib_Name_List_Name>09OMref.enl</w:EN_Lib_Name_List_Name>  </w:DocumentVariables> </w:WordDocument></xml><![endif]--><style><!-- /* Font Definitions */@font-face	{font-family:"Times New Roman";	panose-1:0 2 2 6 3 5 4 5 2 3;	mso-font-charset:0;	mso-generic-font-family:auto;	mso-font-pitch:variable;	mso-font-signature:50331648 0 0 0 1 0;}@font-face	{font-family:Geneva;	panose-1:0 2 11 5 3 3 4 4 4 2;	mso-font-charset:0;	mso-generic-font-family:auto;	mso-font-pitch:variable;	mso-font-signature:50331648 0 0 0 1 0;} /* Style Definitions */p.MsoNormal, li.MsoNormal, div.MsoNormal	{mso-style-parent:"";	margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	font-size:12.0pt;	font-family:Times;}h1	{mso-style-next:Normal;	margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	page-break-after:avoid;	mso-outline-level:1;	font-size:14.0pt;	font-family:Times;	mso-font-kerning:0pt;	font-weight:normal;	font-style:italic;}h2	{mso-style-next:Normal;	margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	page-break-after:avoid;	mso-outline-level:2;	font-size:12.0pt;	font-family:Times;	font-weight:normal;	font-style:italic;}h3	{mso-style-next:Normal;	margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	page-break-after:avoid;	mso-outline-level:3;	font-size:14.0pt;	font-family:Times;	font-style:italic;}h4	{mso-style-next:Normal;	margin:0in;	margin-bottom:.0001pt;	text-align:center;	mso-pagination:widow-orphan;	page-break-after:avoid;	mso-outline-level:4;	font-size:12.0pt;	font-family:Times;}h5	{mso-style-next:Normal;	margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:-27.0pt;	margin-bottom:.0001pt;	text-align:justify;	line-height:150%;	mso-pagination:widow-orphan;	page-break-after:avoid;	mso-outline-level:5;	font-size:14.0pt;	font-family:Times;	font-style:italic;}h6	{mso-style-next:Normal;	margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:-27.0pt;	margin-bottom:.0001pt;	text-align:justify;	line-height:150%;	mso-pagination:widow-orphan;	page-break-after:avoid;	mso-outline-level:6;	font-size:12.0pt;	font-family:Times;	font-style:italic;}p.MsoHeader, li.MsoHeader, div.MsoHeader	{margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	tab-stops:center 3.0in right 6.0in;	font-size:12.0pt;	font-family:Times;}p.MsoFooter, li.MsoFooter, div.MsoFooter	{margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	tab-stops:center 3.0in right 6.0in;	font-size:12.0pt;	font-family:Times;}p.MsoBodyText, li.MsoBodyText, div.MsoBodyText	{margin:0in;	margin-bottom:.0001pt;	text-align:center;	mso-pagination:widow-orphan;	font-size:22.0pt;	font-family:Times;}p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent	{margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:-27.0pt;	margin-bottom:.0001pt;	line-height:150%;	mso-pagination:widow-orphan;	font-size:12.0pt;	font-family:Times;}p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2	{margin:0in;	margin-bottom:.0001pt;	line-height:150%;	mso-pagination:widow-orphan;	font-size:10.0pt;	font-family:Times;}p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3	{margin:0in;	margin-bottom:.0001pt;	text-align:justify;	mso-pagination:widow-orphan;	mso-outline-level:1;	font-size:12.0pt;	font-family:Times;}p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2	{margin-top:0in;	margin-right:0in;	margin-bottom:0in;	margin-left:-27.0pt;	margin-bottom:.0001pt;	text-align:justify;	line-height:150%;	mso-pagination:widow-orphan;	font-size:12.0pt;	font-family:Times;}a:link, span.MsoHyperlink	{color:blue;	text-decoration:underline;	text-underline:single;}a:visited, span.MsoHyperlinkFollowed	{color:purple;	text-decoration:underline;	text-underline:single;}p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap	{margin:0in;	margin-bottom:.0001pt;	mso-pagination:widow-orphan;	background:navy;	font-size:12.0pt;	font-family:Geneva;}table.MsoNormalTable	{mso-style-parent:"";	font-size:10.0pt;	font-family:Times;}@page Section1	{size:8.5in 11.0in;	margin:1.0in 1.0in 1.0in 1.0in;	mso-header-margin:.5in;	mso-footer-margin:.55in;	mso-page-numbers:1;	mso-title-page:yes;	mso-even-header:url(":NystThpys_files:header.htm") eh1;	mso-header:url(":NystThpys_files:header.htm") h1;	mso-even-footer:url(":NystThpys_files:header.htm") ef1;	mso-footer:url(":NystThpys_files:header.htm") f1;	mso-first-header:url(":NystThpys_files:header.htm") fh1;	mso-first-footer:url(":NystThpys_files:header.htm") ff1;	mso-paper-source:0;}div.Section1	{page:Section1;}--></style><!--[if gte mso 9]><xml> <o:shapedefaults v:ext="edit" spidmax="2050"/></xml><![endif]--><!--[if gte mso 9]><xml> <o:shapelayout v:ext="edit">  <o:idmap v:ext="edit" data="1"/> </o:shapelayout></xml><![endif]--></head><body bgcolor=white lang=EN-US link=blue vlink=purple style='tab-interval:.5in'><div class=Section1><p class=MsoBodyText><span style='font-size:16.0pt'><b>Nystagmus Therapies:<o:p></o:p></b></span></p><p class=MsoBodyText><span style='font-size:16.0pt'><b>Types, Sites, andMeasures</b></span><span style='font-size:20.0pt'><b><o:p></o:p></b></span></p><p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoBodyText><span style='font-size:14.0pt;font-family:"Times New Roman"'>L.F.Dell’Osso, Ph.D.<o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center;mso-outline-level:1'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal style='text-align:justify'><span style='font-family:"Times New Roman"'>Fromthe Daroff-Dell’Osso Ocular Motility Laboratory, Louis Stokes Cleveland DVAMedical Center and Depts. of Neurology and Biomedical Engineering, Case WesternReserve University, Cleveland OH, USA</span></p><p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoBodyText align=left style='text-align:left'><span style='font-size:12.0pt'><b>OMLAB Report #111905<o:p></o:p></b></span></p><p class=MsoBodyText align=left style='text-align:left'><span style='font-size:12.0pt'><b>Written:</b></span><span style='font-size:12.0pt'> 2/20/05; <b>Placedon Web Page:</b></span><span style='font-size:12.0pt'> 11/19/05; <b>LastModified:</b></span><span style='font-size:12.0pt'> 11/22/05<o:p></o:p></span></p><p class=MsoBodyText align=left style='text-align:left'><span style='font-size:12.0pt'><b>Downloaded from:</b></span><span style='font-size:12.0pt'> OMLAB.ORG<o:p></o:p></span></p><p class=MsoNormal><b>Send questions, comments, and suggestions to:</b><spanstyle='font-weight:normal'> lfd@case.edu</span></p><p class=MsoBodyText3><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoBodyText3><span style='font-size:10.0pt'>This work was supported inpart by the Office of Research and Development, Medical Research Service,Department of Veterans Affairs.<o:p></o:p></span></p><p class=MsoNormal style='text-align:justify'><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='text-align:justify;mso-outline-level:1'><spanstyle='font-size:10.0pt'>Presented in part at the 2005 NANOS meeting.<o:p></o:p></span></p><p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal>Current therapies for nystagmus fall into two majorcategories, <i>central</i><span style='font-style:normal'> and </span><i>peripheral</i><spanstyle='font-style:normal'>. Central therapies may be neurosurgical or pharmacological;each is directed at the central source of the nystagmus and its aim is todirectly reduce the initiating, brain-stem nystagmus signal (the motorcommand). Peripheral therapies may be pharmacological, optical, or surgical;each is directed at a peripheral mechanism to directly reduce the resulting eyeoscillation without affecting the brain-stem nystagmus motor command. Oneadditional, new therapy that may affect nystagmus is </span><i>afferent</i><spanstyle='font-style:normal'> therapy. An example is gene therapy applied to theretina to correct genetic deficits that impair vision directly and mayfacilitate the development of nystagmus (e.g., RPE65 deficiency and infantilenystagmus syndrome (INS)) </span><!--[if supportFields]><span style='mso-element:field-begin'></span><span style="mso-spacerun: yes">&nbsp;</span>ADDIN EN.CITE&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;CEMAS_Working_Group&lt;/Author&gt;&lt;Year&gt;2001&lt;/Year&gt;&lt;RecNum&gt;14&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;10&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;CEMAS_Working_Group&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2001&lt;/YEAR&gt;&lt;TITLE&gt;ANational Eye Institute Sponsored Workshop and Publication on The Classificationof Eye Movement Abnormalities and Strabismus (CEMAS). In The National EyeInstitute Publications(www.nei.nih.gov)&lt;/TITLE&gt;&lt;PLACE_PUBLISHED&gt;Bethesda,MD&lt;/PLACE_PUBLISHED&gt;&lt;PUBLISHER&gt;National Institutes of Health,National Eye Institute&lt;/PUBLISHER&gt;&lt;LABEL&gt;5.89&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;NYST:STRAB:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;<spanstyle='mso-element:field-separator'></span><![endif]-->(1)<!--[if supportFields]><spanstyle='mso-element:field-end'></span><![endif]-->. The accompanying Figureillustrates the anatomical sites of: each type of therapy; theneurophysiological signals present; and the measurements of each therapy’sdirect and indirect effects. The ocular motor system is centered in the brainstem with multiple connections to the cerebellum and cortex.</p><p class=MsoNormal style='line-height:150%'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal>The most accurate measure of any therapy is a measure of its<i>direct</i><span style='font-style:normal'> effects, not an indirect measureof a neurophysiological function that is dependent on other interveningfunctions, each subject to idiosyncratic deficits. Therefore, the primaryoutcome measure of a therapy should be a measure of the therapy’s directeffects&#8212;regardless of a desired medical outcome, which is usually onlyindirectly related to those effects. Unfortunately, evaluations of theeffectiveness of nystagmus therapies commonly substitute one medicallydesirable, indirect outcome (i.e., improved primary-position visual acuity) formore direct measures of each therapy. Succumbing to that temptation is neithergood science nor good medicine&#8212;the results are not a valid measure oftherapies whose direct effects do not lie in the pathway from afferent input tovisual discrimination. It also eliminates other, often more important, measuresof visual function. Many patients with INS have one or more afferent visualdeficits that limit potential visual acuity, whether or not they were relatedto the series of events in the motor system that resulted in ocular motorinstability. Finally, even for those with no afferent deficits, mental status(stress) often results in a measured visual acuity that is lower than theacuity achieved during normal life. Therefore, using indirect measures fardownstream from a nystagmus therapy’s direct effects will result in confoundedmeasurements reflecting variations in the patient population’s afferent systemsor stress levels rather than the effectiveness of the therapies (e.g., measuredprimary-position visual acuity improvement is </span><i>not</i><spanstyle='font-style:normal'> a valid measure of the effectiveness of nystagmussurgery).</span></p><p class=MsoNormal style='line-height:150%'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal style='line-height:150%'><b><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas>  <v:f eqn="if lineDrawn pixelLineWidth 0"/>  <v:f eqn="sum @0 1 0"/>  <v:f eqn="sum 0 0 @1"/>  <v:f eqn="prod @2 1 2"/>  <v:f eqn="prod @3 21600 pixelWidth"/>  <v:f eqn="prod @3 21600 pixelHeight"/>  <v:f eqn="sum @0 0 1"/>  <v:f eqn="prod @6 1 2"/>  <v:f eqn="prod @7 21600 pixelWidth"/>  <v:f eqn="sum @8 21600 0"/>  <v:f eqn="prod @7 21600 pixelHeight"/>  <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/></v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:467pt; height:331pt'> <v:imagedata src="NystThpys_files/image001.gif" o:althref="NystThpys_files/image002.pct"  o:title=""/></v:shape><![endif]--><![if !vml]><img width=467 height=331src="NystThpys_files/image003.png" v:shapes="_x0000_i1025"><![endif]><o:p></o:p></b></p><p class=MsoNormal><span style='font-size:11.0pt'><b>Figure.</b></span><spanstyle='font-size:11.0pt'> A block diagram of the ocular motor system indicatingthe types of therapeutic intervention for nystagmus, their anatomic sites, anddirect and indirect measurements of their effectiveness. Ta is afferent therapyfor deficits in the visual system (shown here is gene therapy for retinaldeficiencies), Tc is central (neurosurgical or drug) therapy for nystagmus, andTp is peripheral (surgical, optical, or drug) therapy for nystagmus. Shown insquare brackets are the sites of therapeutic tests of visual and ocular motorfunction. The direct and indirect effects of each type of therapy and thedirect and indirect outcome measures for each are listed in the Legend Boxes.e=retinal error; n=nystagmus error; E=eye position; N=nystagmus; F=extraocularmuscle force; Fn=extraocular muscle nystagmus force; ERG=electroretinogram;PLR=pupillary light reflex; VEP=visual evoked potential; EMG=electromyogram;NAFX=expanded nystagmus acuity function; +=improved, higher, or better; -=diminished,lower, or less; blue/light-blue blocks=afferent sensory; blue/yellowblock=afferent-efferent sensorimotor; red/yellow blocks=efferent motor; andblack/orange blocks=therapies.<o:p></o:p></span></p><p class=MsoNormal style='line-height:150%'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal>The ideal measure of any nystagmus therapy is one that isboth a direct outcome measure of that therapy and, if possible, a predictivemeasure of the medical goals of improved primary-position acuity and <i>improvedvisual function</i><span style='font-style:normal'>. As the Figure shows, theelectroretinogram, pupillary light reflex, and visual evoked potential are themost direct measures for afferent therapies. Each is predictive of visualacuity, which is determined slightly upstream, albeit requiring higher corticalfunction. In animal studies, where visual acuity is not easily measured, theeXpanded Nystagmus Acuity Function (NAFX) </span><!--[if supportFields]><spanstyle='mso-element:field-begin'></span><span style="mso-spacerun:yes">&nbsp;</span>ADDIN EN.CITE&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Dell&amp;apos;Osso&lt;/Author&gt;&lt;Year&gt;2002&lt;/Year&gt;&lt;RecNum&gt;12&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Dell&amp;apos;Osso,L. F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Jacobs, J.B.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2002&lt;/YEAR&gt;&lt;TITLE&gt;Anexpanded nystagmus acuity function: intra- and intersubject prediction ofbest-corrected visual acuity&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;DocOphthalmol&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;104&lt;/VOLUME&gt;&lt;PAGES&gt;249-276&lt;/PAGES&gt;&lt;LABEL&gt;5.63&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;NAFX:CN:VACTY:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;<spanstyle='mso-element:field-separator'></span><![endif]-->(2)<!--[if supportFields]><spanstyle='mso-element:field-end'></span><![endif]--> provides an easilyobtainable, <i>in vivo</i><span style='font-style:normal'> measure of genetherapy’s effectiveness by measuring nystagmus waveform improvements </span><!--[if supportFields]><spanstyle='mso-element:field-begin'></span><span style="mso-spacerun:yes">&nbsp;</span>ADDIN EN.CITE&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Jacobs&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;19&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;16&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Jacobs,J. B.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dell&amp;apos;Osso, L.F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hertle, R. W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Bennett,J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Acland, G.M.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;TITLE&gt;Genetherapy to abolish congenital nystagmus in RPE65-deficientcanines&lt;/TITLE&gt;&lt;PUBLISHER&gt;Annual Meeting Abstract and ProgramPlanner [on CD-ROM or accessed atwww.arvo.org]&lt;/PUBLISHER&gt;&lt;PAGES&gt;ARVO Abstr 4249&lt;/PAGES&gt;&lt;LABEL&gt;5.145&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;CN:LCA:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;<spanstyle='mso-element:field-separator'></span><![endif]-->(3)<!--[if supportFields]><spanstyle='mso-element:field-end'></span><![endif]-->. Although an indirect measureof afferent therapy, the NAFX predicts potential acuity. For central andperipheral therapies, the best and least invasive direct measure is the NAFX;the electromyogram is both invasive and not easily related to visual acuity.Because the NAFX both predicts acuity improvements and measures increases inthe range of gaze angles over which those improvements are present, it waschosen as the primary outcome measure of two masked clinical trials of theeffectiveness of tenotomy <!--[if supportFields]><span style='mso-element:field-begin'></span><spanstyle="mso-spacerun: yes">&nbsp;</span>ADDIN EN.CITE&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Dell&amp;apos;Osso&lt;/Author&gt;&lt;Year&gt;1999&lt;/Year&gt;&lt;RecNum&gt;7&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Dell&amp;apos;Osso,L. F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Hertle, R.W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Williams, R.W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Jacobs, J.B.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;1999&lt;/YEAR&gt;&lt;TITLE&gt;Anew surgery for congenital nystagmus: effects of tenotomy on an achiasmaticcanine and the role of extraocular proprioception&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;JAAPOS&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;3&lt;/VOLUME&gt;&lt;PAGES&gt;166-182&lt;/PAGES&gt;&lt;LABEL&gt;0.431&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;CN:ACMBS: SURG: RR: BMR: TENOT:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;Cite&gt;&lt;Author&gt;Dell&amp;apos;Osso&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&gt;&lt;RecNum&gt;6&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Dell&amp;apos;Osso,L.F.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;1998&lt;/YEAR&gt;&lt;TITLE&gt;Extraocularmuscle tenotomy, dissection, and suture: A hypothetical therapy for congenitalnystagmus&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;J Pediatr OphthalmolStrab&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;35&lt;/VOLUME&gt;&lt;PAGES&gt;232-233&lt;/PAGES&gt;&lt;LABEL&gt;4.497&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;CN:SURG:TENOT:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;<spanstyle='mso-element:field-separator'></span><![endif]-->(4,5)<!--[if supportFields]><spanstyle='mso-element:field-end'></span><![endif]--> in the treatment of infantilenystagmus in adults <!--[if supportFields]><span style='mso-element:field-begin'></span><spanstyle="mso-spacerun: yes">&nbsp;</span>ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Hertle&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;8&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Hertle,R.W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dell&amp;apos;Osso, L. F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;FitzGibbon,E. J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thompson,D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Yang, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Mellow, S.D.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2003&lt;/YEAR&gt;&lt;TITLE&gt;Horizontalrectus tenotomy in patients with congenital nystagmus. Results in 10adults&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;Ophthalmology&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;110&lt;/VOLUME&gt;&lt;PAGES&gt;2097-2105&lt;/PAGES&gt;&lt;LABEL&gt;5.147&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;CN:SURG:TENOT:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;<spanstyle='mso-element:field-separator'></span><![endif]-->(6)<!--[if supportFields]><spanstyle='mso-element:field-end'></span><![endif]--> and children <!--[if supportFields]><spanstyle='mso-element:field-begin'></span><span style="mso-spacerun:yes">&nbsp;</span>ADDIN EN.CITE&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Hertle&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;28&lt;/RecNum&gt;&lt;MDL&gt;&lt;REFERENCE_TYPE&gt;0&lt;/REFERENCE_TYPE&gt;&lt;AUTHORS&gt;&lt;AUTHOR&gt;Hertle,R.W.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Dell&amp;apos;Osso, L.F.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;FitzGibbon, E.J.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Thompson, D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Yang,D.&lt;/AUTHOR&gt;&lt;AUTHOR&gt;Mellow, S. D.&lt;/AUTHOR&gt;&lt;/AUTHORS&gt;&lt;YEAR&gt;2004&lt;/YEAR&gt;&lt;TITLE&gt;Horizontalrectus muscle tenotomy in patients with infantile nystagmus syndrome: a pilotstudy&lt;/TITLE&gt;&lt;SECONDARY_TITLE&gt;JAAPOS&lt;/SECONDARY_TITLE&gt;&lt;VOLUME&gt;8&lt;/VOLUME&gt;&lt;PAGES&gt;539-548&lt;/PAGES&gt;&lt;LABEL&gt;5.176&lt;/LABEL&gt;&lt;KEYWORDS&gt;&lt;KEYWORD&gt;CN:SURG:TENOT:&lt;/KEYWORD&gt;&lt;/KEYWORDS&gt;&lt;/MDL&gt;&lt;/Cite&gt;&lt;/EndNote&gt;<spanstyle='mso-element:field-separator'></span><![endif]-->(7)<!--[if supportFields]><spanstyle='mso-element:field-end'></span><![endif]-->. In many patients with INS,increasing the effective high-acuity visual field does far more to improvevisual function than simply increasing Snellen acuity in one small region ofthe visual field&#8212;unfortunately, this is neither appreciated nor commonlymeasured in the physician's office. It does explain why a given therapy mayresult in a patient reporting that he can “see better” even when the pre- andpost-therapeutic primary-position Snellen acuities are essentially equal.</p><p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal>As the Figure illustrates, peripheral surgical therapy actsat the muscle to damp the resulting nystagmus; it does not change thebrain-stem nystagmus signal itself. Also, it is equally effective in dampingboth infantile and acquired nystagmus (the muscle cannot determine the origin ofthe nystagmus signal). Central pharmacological therapy is administered to dampthe brain-stem nystagmus signal. Because of their independence, if both centraland peripheral therapies are applied together (in either order), the resultwill be the multiplicative damping from both therapies. This type of‘dual-mode’ therapy has been shown to maximally damp the nystagmus andmaximally improve visual function.</p><p class=MsoHeader style='line-height:150%;tab-stops:.5in'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoHeader style='line-height:150%;tab-stops:.5in'><b>REFERENCES<o:p></o:p></b></p><p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><!--[if supportFields]><spanstyle='font-size:10.0pt'><span style='mso-element:field-begin'></span><spanstyle="mso-spacerun: yes">&nbsp;</span>ADDIN EN.REFLIST <span style='mso-element:field-separator'></span></span><![endif]--><span style='font-size:10.0pt'>1.<spanstyle='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>CEMAS_Working_Group.<i>A National Eye Institute Sponsored Workshop and Publication on TheClassification of Eye Movement Abnormalities and Strabismus (CEMAS). In TheNational Eye Institute Publications (<a href="http://www.nei.nih.gov)/">www.nei.nih.gov)</a></i></span><spanstyle='font-size:10.0pt'>. 2001, National Institutes of Health, National EyeInstitute: Bethesda, MD.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><spanstyle='font-size:10.0pt'>2.<span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Dell'OssoLF, Jacobs JB. An expanded nystagmus acuity function: intra- and intersubjectprediction of best-corrected visual acuity<i>.</i></span><spanstyle='font-size:10.0pt'> <i>Doc Ophthalmol</i></span><span style='font-size:10.0pt'> 2002; 104:249-76.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><spanstyle='font-size:10.0pt'>3.<span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>JacobsJB, Dell'Osso LF, Hertle RW, Bennett J, Acland GM. <i>Gene therapy to abolishcongenital nystagmus in RPE65-deficient canines</i></span><spanstyle='font-size:10.0pt'>. 2003, Annual Meeting Abstract and Program Planner[on CD-ROM or accessed at <a href="http://www.arvo.org%5D/">www.arvo.org]</a>.p. ARVO Abstr 4249.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><spanstyle='font-size:10.0pt'>4.<span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Dell'OssoLF, Hertle RW, Williams RW, Jacobs JB. A new surgery for congenital nystagmus:effects of tenotomy on an achiasmatic canine and the role of extraocularproprioception<i>.</i></span><span style='font-size:10.0pt'> <i>J AAPOS</i></span><spanstyle='font-size:10.0pt'> 1999; 3:166-82.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><spanstyle='font-size:10.0pt'>5.<span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Dell'OssoLF. Extraocular muscle tenotomy, dissection, and suture: A hypothetical therapyfor congenital nystagmus<i>.</i></span><span style='font-size:10.0pt'> <i>JPediatr Ophthalmol Strab</i></span><span style='font-size:10.0pt'> 1998;35:232-3.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><spanstyle='font-size:10.0pt'>6.<span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>HertleRW, Dell'Osso LF, FitzGibbon EJ, Thompson D, Yang D, Mellow SD. Horizontalrectus tenotomy in patients with congenital nystagmus. Results in 10 adults<i>.</i></span><spanstyle='font-size:10.0pt'> <i>Ophthalmology</i></span><span style='font-size:10.0pt'> 2003; 110:2097-105.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><spanstyle='font-size:10.0pt'>7.<span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>HertleRW, Dell'Osso LF, FitzGibbon EJ, Thompson D, Yang D, Mellow SD. Horizontalrectus muscle tenotomy in patients with infantile nystagmus syndrome: a pilotstudy<i>.</i></span><span style='font-size:10.0pt'> <i>JAAPOS</i></span><spanstyle='font-size:10.0pt'> 2004; 8:539-48.<o:p></o:p></span></p><p class=MsoHeader style='tab-stops:.5in'><!--[if supportFields]><spanstyle='font-size:10.0pt'><span style='mso-element:field-end'></span></span><![endif]--><spanstyle='font-size:14.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal style='line-height:150%'><b><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></b></p><h2><b>Citation<o:p></o:p></b></h2><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal>Although the information contained in this paper and itsdownloading are free, please acknowledge its source by citing the paper asfollows:<o:p></o:p></p><p class=MsoNormal><span style='font-size:10.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt;color:black'>Dell’Osso, L.F.:Nystagmus Therapies: Types, Sites, and Measures. OMLAB Report #111905, 1-4,2005. </span><span style='font-size:10.0pt'><ahref="http://www.omlab.org/Teaching/teaching.html">http://www.omlab.org/Teaching/teaching.html</a><o:p></o:p></span></p><p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt'><b>Note: </b></span><spanstyle='font-size:11.0pt'><i>This report was originally numbered as #112005 andwas corrected to #111905 (date posted) on February 7, 2008.</i></span></p></div></body></html>